EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

AbbVie’s Rinvoq notches Crohn’s disease win amid classwide JAK safety concerns

AbbVie's blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn's disease patients, potentially adding another arrow to the company's post-Humir...
Continue Reading →
news

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-d...
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18